Evidence map›Paper›PMID 40603425›Full record

ArticleScientific reports2025

Updated Japanese multicenter registry study evaluates the efficacy and safety of proton beam therapy for treating extrahepatic cholangiocarcinoma.

Hideya Yamazaki, Kei Shibuya, Takuya Kimoto, Motohisa Suzuki, Masao Murakami, Kazuki Terashima, Tomoaki Okimoto, Takashi Iizumi, Hideyuki Sakurai, Masaru Wakatsuki and 13 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Hideya YamazakiDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. hideya10@hotmail.com.
Kei ShibuyaGunma University Heavy Ion Medical Center, Maebashi, Japan.
Takuya KimotoDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Motohisa SuzukiDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Koriyama, Japan.
Masao MurakamiDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Koriyama, Japan.
Kazuki TerashimaDepartment of Radiology, Hyogo Ion Beam Medical Center, Hyogo, Japan.
Tomoaki OkimotoDepartment of Radiology, Hyogo Ion Beam Medical Center, Hyogo, Japan.
Takashi IizumiDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, Japan.
Hideyuki SakuraiDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, Japan.
Masaru WakatsukiQST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Takashi OginoMedipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan.
Takeshi ArimuraMedipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan.
Masaru TakagiProton Therapy Center, Sapporo Teishinkai Hospital, Sapporo, Hokkaido, Japan.
Masayuki ArayaProton Therapy Center, Aizawa Hospital, Matsumoto, Nagano, Japan.
Takahiro WakiDepartment of Radiology, Tsuyama Chuo Hospital, Tsuyama, Okayama, Japan.
Sae MatsumotoProton Therapy Center, Fukui Prefectural Hospital, Fukui, Japan.
Hiroyuki OginoDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Norio KatohDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Takayuki HashimotoGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Hidehiro HojoDepartment of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Nobuyoshi FukumitsuDepartment of Radiation Oncology, Kobe Proton Center, Kobe, Japan.
Takumi FukumotoDepartment of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Masayuki OhtsukaDepartment of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to analyze the efficacy and safety of a prospective, multicenter registry study of proton beam therapy (PBT) for extrahepatic cholangiocarcinoma (EHC) in Japan. Patients who underwent PBT for EHC between May 2016 and June 2021 were registered in the Particle Beam Therapy Committee and Subcommittee of the Japanese Society for Radiation Oncology. We updated the overall survival (OS), progression-free survival (PFS), local control rate (LC), and toxicity. Among 201 registered cases, 124 cases including elder population (median age 76 years old, range; 44-91) with initial definitive PBT were evaluated. The follow-up period for survivors was 18.3 months, the median OS time was 20.0 months (95% CI: 17.3-22.8 months), and the 2-year OS rate was 36.9% (27.3-46.4%). The 2-year LC and PFS were 65.2% and 23.0%. The OS was significantly higher for tumor size < 3 cm vs. ≥ 3 cm (p = 0.015); liver function Child-Pugh score normal/A vs. B/C (p < 0.001); and distance of the tumor from the gastrointestinal tract > 2 cm vs. ≤ 2 cm (p = 0.008) in multivariate analysis. Elderly patients age > 75 years underwent less chemotherapy and showed a 2-year OS of 41.3%, whereas young patients with age ≤ 75 years showed a 2-year OS of 32.0%. A higher prescribed dose (biologically effective dose: BED) > 89 Gy

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaProton TherapyAdultAgedAged, 80 and overEast Asian PeopleFemaleHumansJapanMaleMiddle AgedProspective StudiesRegistriesTreatment OutcomeCholangiocarcinomaElderly patientsExtrahepatic bile duct cancerProton beam therapy

Identifiers

PMID40603425
PMCPMC12222466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.